Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research
Farwa Jafri(Kansas City University), Valentina Shakhnovich(Ironwood Pharmaceuticals (United States)), Zachary L. Taylor(Cincinnati Children's Hospital Medical Center), Daniel González(University of North Carolina at Chapel Hill)
Cited by 4
Related Papers
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
|Obesity|2021|199
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
|Clinical Therapeutics|2016|170
Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents
|Clinical Microbiology Reviews|2013|147